{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:49:00Z","timestamp":1768967340410,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/maj.0b013e31825140a7","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T23:45:46Z","timestamp":1335397546000},"page":"350-352","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Ankylosing Spondylitis: A Critical Appraisal of Nonsteroidal Anti-Inflammatory Drugs and Corticosteroids"],"prefix":"10.1016","volume":"343","author":[{"given":"Muhammad A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Garcia-Kutzbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis R.","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Clegg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31825140a7_bb0005","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1517\/14656566.2011.604313","article-title":"Current therapeutics for spondyloarthritis","volume":"12","author":"Toussirot","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrrheum.2009.258","article-title":"Disease modification in ankylosing spondylitis","volume":"6","author":"Maksymowych","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0015","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00296-009-0973-9","article-title":"A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis","volume":"29","author":"Goh","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11926-010-0125-y","article-title":"Update on biological therapy in the management of axial spondyloarthritis","volume":"12","author":"Heldmann","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0025","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/rheumatology\/ker270","article-title":"Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide","volume":"50","author":"Van den Berg","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11926-006-0005-7","article-title":"The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis","volume":"8","author":"Elyan","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0035","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/ EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00393-006-0119-3","article-title":"Recommendations for the management of ankylosing spondylitis after ASAS\/EULAR. Evaluation in the German language area","volume":"65","author":"Braun","year":"2006","journal-title":"Z Rheumatol"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jbspin.2007.04.003","article-title":"Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion","volume":"74","author":"Lavie","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0050","first-page":"784","article-title":"Evidence based recommendations for the management of ankylosing spondylitis: results of the Hellenic working group of the 3E Initiative in Rheumatology","volume":"26","author":"Raptopoulou","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0055","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0060","first-page":"1805","article-title":"Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis","volume":"33","author":"Barkhuizen","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib and diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0070","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","article-title":"Nonsteroidal antiinflammatory drug use in ankylosing spondylitis\u2014a population-based survey","volume":"25","author":"Zochling","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0075","series-title":"Spondyloarthritis treatment: review in Central American and Caribbean","author":"Garcia-Kuztbach","year":"2011"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0080","first-page":"118","article-title":"A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis","volume":"14","author":"Khan","year":"1987","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0085","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0090","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1136\/ard.2008.092213","article-title":"MRI and clinical findings in ankylosing spondylitis patients eligible for anti-tumor necrosis factor therapy after a short course of etoricoxib","volume":"68","author":"Jarret","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0095","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0100","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/ard.2008.100503","article-title":"Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study","volume":"68","author":"Vosse","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0105","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0110","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2165\/00003495-200969110-00008","article-title":"Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/11314690-000000000-00000","article-title":"Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDs in the treatment of ankylosing spondylitis","volume":"28","author":"Jansen","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00296-009-0963-y","article-title":"Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study","volume":"30","author":"Cinar","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0125","first-page":"S520","article-title":"Profiling NSAID responders in ankylosing spondylitis","volume":"63","author":"Alnaqbi","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0130","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/keq078","article-title":"Evaluation of the treatment effect of NSAIDs\/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis","volume":"49","author":"Escalas","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2010.133488","article-title":"ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/ epidemiological studies in axial spondyloarthritis","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0140","first-page":"S971","article-title":"Non-steroidal antiinflammatory drugs reduce radiographic spinal progression in patients with ankylosing spondylitis but not in non-radiographic axial spondyloarthritis","volume":"63","author":"Poddubnyy","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10354-008-0521-3","article-title":"Issues in the treatment of ankylosing spondylitis with non-steroidal anti-inflammatory drugs","volume":"158","author":"van der Linden","year":"2008","journal-title":"Wien Med Wochenschr"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0150","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3748\/wjg.v17.i8.1030","article-title":"NSAID-induced deleterious effects on the proximal and mid small bowel in seronegative spondyloarthropathy patients","volume":"17","author":"Rimbas","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/14740338.7.4.401","article-title":"The safety of celecoxib in ankylosing spondylitis treatment","volume":"7","author":"Poddunbnyy","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1097\/MAJ.0b013e31825140a7_bb0160","first-page":"S139","article-title":"Glucocorticoid treatment in spondyloarthritis","volume":"29","author":"Fendler","year":"2011","journal-title":"Clin Exp Rheumatol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915309617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T21:25:57Z","timestamp":1543008357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915309617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0002962915309617"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31825140a7","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}